PD09-05 STANDARD VERSUS EXTENDED LYMPH NODE DISSECTION AT THE TIME OF RADICAL CYSTECTOMY FOR BLADDER CANCER

医学 膀胱切除术 膀胱癌 解剖(医学) 淋巴结切除术 淋巴结 随机对照试验 普通外科 泌尿科 癌症 外科 内科学
作者
Alejandro Abello,Sumedh Kaul,Aaron Fleishman,Joaquim Bellmunt,Irving Kaplan,Simon Kim,Peter Chang,Andrew Wagner,Ruslan Korets,Aria F. Olumi,Boris Gershman
出处
期刊:The Journal of Urology [Lippincott Williams & Wilkins]
卷期号:209 (Supplement 4)
标识
DOI:10.1097/ju.0000000000003240.05
摘要

You have accessJournal of UrologyCME1 Apr 2023PD09-05 STANDARD VERSUS EXTENDED LYMPH NODE DISSECTION AT THE TIME OF RADICAL CYSTECTOMY FOR BLADDER CANCER Alejandro Abello, Sumedh Kaul, Aaron Fleishman, Joaquim Bellmunt, Irving Kaplan, Simon Kim, Peter Chang, Andrew Wagner, Ruslan Korets, Aria Olumi, and Boris Gershman Alejandro AbelloAlejandro Abello More articles by this author , Sumedh KaulSumedh Kaul More articles by this author , Aaron FleishmanAaron Fleishman More articles by this author , Joaquim BellmuntJoaquim Bellmunt More articles by this author , Irving KaplanIrving Kaplan More articles by this author , Simon KimSimon Kim More articles by this author , Peter ChangPeter Chang More articles by this author , Andrew WagnerAndrew Wagner More articles by this author , Ruslan KoretsRuslan Korets More articles by this author , Aria OlumiAria Olumi More articles by this author , and Boris GershmanBoris Gershman More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003240.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: It is uncertain whether lymphadenectomy (LND) provides a survival benefit in patients undergoing radical cystectomy (RC). In the only completed randomized trial on this topic – LEA AUO AB 25/02 – extended LND (eLND) was associated with improved survival compared to limited/standard (sLND), although these associations did not reach statistical significance. Herein, we emulated a pragmatic clinical trial designed to resemble the LEA trial. METHODS: We identified patients in the National Cancer Database who met the following eligibility criteria based on the LEA trial: adult 40-79 years old, Charlson 0-1, underwent RC with LND for high-grade cT1/cT2-T4a cNany cM0 urothelial carcinoma of the bladder from 2006-2015, without neoadjuvant chemotherapy, at a hospital performing ≥16 RC/year. sLND and eLND were defined as removal of 4-11 and ≥12 lymph nodes based on the LEA trial. A propensity score (PS) was estimated for receipt of eLND, and the associations of LND type with overall survival (OS) were evaluated adjusting with inverse probability of treatment weights (IPW). RESULTS: A total of 2248 patients formed the study cohort, including 429 with sLND and 1813 with eLND. Baseline characteristics were well-balanced after PS adjustment. During a median follow-up of 37.5 months, eLND was associated with significantly improved 5-year OS compared to sLND (60% vs 48%; HR 0.72, 95%CI: 0.61-0.85, p<0.01; Figure 1). Effect estimates were consistent across all potential treatment effect modifiers, including cT stage, cN stage, and age (Figure 2). Results were robust in sensitivity analyses that modified the definitions for LND and relaxed the annual RC hospital volume requirement. CONCLUSIONS: In observational analyses designed to emulate a completed clinical trial, eLND was associated with improved OS compared to sLND among patients undergoing RC. Survival and effect estimates were similar to those in the LEA trial but statistically significant due to larger sample size. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e241 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Alejandro Abello More articles by this author Sumedh Kaul More articles by this author Aaron Fleishman More articles by this author Joaquim Bellmunt More articles by this author Irving Kaplan More articles by this author Simon Kim More articles by this author Peter Chang More articles by this author Andrew Wagner More articles by this author Ruslan Korets More articles by this author Aria Olumi More articles by this author Boris Gershman More articles by this author Expand All Advertisement PDF downloadLoading ...

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lou发布了新的文献求助10
刚刚
刚刚
深情安青的应助被腼腆的水蓝采纳,获得10
1秒前
郑方形完成签到,获得积分10
4秒前
4秒前
隐形曼青的应助被zm采纳,获得10
4秒前
4秒前
sun发布了新的文献求助30
4秒前
脑洞疼的应助被maT采纳,获得10
5秒前
愉快的千青完成签到,获得积分20
5秒前
不如吃茶去完成签到,获得积分10
5秒前
香蕉觅云的应助被科研通管家采纳,获得10
6秒前
乐乐的应助被科研通管家采纳,获得30
6秒前
FashionBoy的应助被科研通管家采纳,获得10
6秒前
CodeCraft的应助被科研通管家采纳,获得10
6秒前
FashionBoy的应助被科研通管家采纳,获得10
6秒前
脑洞疼的应助被科研通管家采纳,获得10
6秒前
星星完成签到,获得积分10
6秒前
大个的应助被tomatoGG采纳,获得10
6秒前
我是老大的应助被科研通管家采纳,获得10
6秒前
Owen的应助被科研通管家采纳,获得10
6秒前
桐桐的应助被科研通管家采纳,获得30
7秒前
爆米花的应助被科研通管家采纳,获得10
7秒前
molihuakai的应助被科研通管家采纳,获得10
7秒前
Lucas的应助被科研通管家采纳,获得10
7秒前
合适乐巧发布了新的文献求助10
7秒前
7秒前
7秒前
在水一方的应助被科研通管家采纳,获得10
7秒前
7秒前
大模型的应助被科研通管家采纳,获得10
7秒前
Akim的应助被科研通管家采纳,获得10
7秒前
无花果的应助被科研通管家采纳,获得10
8秒前
李爱国的应助被科研通管家采纳,获得10
8秒前
落纸云烟发布了新的文献求助50
8秒前
晴天完成签到,获得积分10
9秒前
10秒前
10秒前
沉默发布了新的文献求助10
11秒前
MAthor发布了新的文献求助10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178960
求助须知:如何正确求助?哪些是违规求助? 9569638
关于积分的说明 21805682
捐赠科研通 7774071
什么是DOI,文献DOI怎么找? 3432955
关于科研通互助平台的介绍 2556897
邀请新用户注册赠送积分活动 2478640